Humacyte reports Q1 EPS 28c, consensus (21c)

Reports Q1 revenue $517k, consensus $764.83k. “The U.S. commercial launch of Symvess this quarter was a major milestone for Humacyte (HUMA), and we are excited to provide this transformative product to surgeons and patients in need of a new option to save limbs and lives,” said Laura Niklason, M.D., Ph.D., Founder and Chief Executive Officer of Humacyte. “Supporting the launch is our number one priority and we are pleased by the traction gained in our interactions with hospitals, despite the current volatile economic environment. Only a few months after commercial launch, we are excited that 45 hospitals have already commenced an evaluation of Symvess as part of their Value Analysis Committee approval process – approximately one quarter of all Level 1 trauma centers nationwide.”